SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 197.62+0.1%12:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Russian Bear who wrote (13648)1/23/1998 9:19:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
RB, I don't have any hard data on a droloxifene/raloxifene comparison. PFE's press release suggests that the interim look at droloxifene suggests that it's better than currently available treatments for osteoporosis, and I think that raloxifene (Evista) falls into the "currently available" category. There's clearly room for improvement on Evista, which is part of the reason LLY is looking to combine a SERM and Rexinoid (and although the LGND program is for cancer, I suspect that synergies will be applicable to osteoporosis).

I don't think that the osteoporosis application is slated for NDA submission for several years. I don't think that Phase III has begun yet for osteoporosis, but I think that the "acceleration" would dictate a start very soon. The Phase II trial began awhile ago, I believe (it's hard to get hard data from PFE).

LGND thinks that CP-366,156 is better than Droloxifene. PFE has begun European trials and US trials are slated to being this year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News